Stability of Diluted Adenosine Solutions in Polyolefin Infusion Bags by Almagambetova, Elise et al.
St. John Fisher College 
Fisher Digital Publications 
Doctoral External Publications 
6-1-2013 
Stability of Diluted Adenosine Solutions in Polyolefin Infusion 
Bags 
Elise Almagambetova 
St. John Fisher College, emb01556@students.sjfc.edu 
David Hutchinson 
St. John Fisher College, dhutchinson@sjfc.edu 
Danielle M. Blais 
The Ohio State University 
Fang Zhao 
St. John Fisher College, fzhao@sjfc.edu 
Follow this and additional works at: https://fisherpub.sjfc.edu/doctoral_ext_pub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
How has open access to Fisher Digital Publications 
benefited you? 
Publication Information 
Almagambetova, Elise; Hutchinson, David; Blais, Danielle M.; and Zhao, Fang (2013). "Stability of Diluted 
Adenosine Solutions in Polyolefin Infusion Bags." Hospital Pharmacy 48.6, 484-488. 
Please note that the Publication Information provides general citation information and may not be 
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit 
http://libguides.sjfc.edu/citations. 
This document is posted at https://fisherpub.sjfc.edu/doctoral_ext_pub/27 and is brought to you for free and open 
access by Fisher Digital Publications at St. John Fisher College. For more information, please contact 
fisherpub@sjfc.edu. 
Stability of Diluted Adenosine Solutions in Polyolefin Infusion Bags 
Abstract 
Background 
Intravenous or intracoronary adenosine is used in the cardiac catherization lab to achieve maximal 
coronary blood flow and determine fractional flow reserve. 
Objective 
To determine the stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5% 
dextrose injection in polyolefin infusion bags stored at 2 temperatures, refrigeration (2°C-8°C) or 
controlled room temperature (20°C-25°C). 
Methods 
Adenosine 10 µg/mL and 50 µg/mL solutions were prepared in 50 mL polyolefin infusion bags containing 
0.9% sodium chloride injection or 5% dextrose injection and stored at controlled room temperature or 
under refrigeration. Each combination of concentration, diluent, and storage was prepared in triplicate. 
Samples were assayed using stability-indicating, reversed-phase high-performance liquid chromatography 
immediately at time 0 and at 24 hours, 48 hours, 7 days, and 14 days. Stability was defined as retaining 
90% to 110% of the initial adenosine concentration. The samples were also visually inspected against a 
light background for clarity, color, and the presence of particulate matter. 
Results 
After 14 days, all samples retained 99% to 101% of the initial adenosine concentration. No considerable 
change in pH or visual appearance was noted. The stability data indicated no significant loss of drug due 
to chemical degradation or physical interactions during storage. 
Conclusion 
Adenosine solutions of 10 and 50 µg/mL were stable for at least 14 days in 50 mL polyolefin infusion 
bags of 0.9% sodium chloride injection or 5% dextrose injection stored at controlled room temperature 
and refrigerated conditions. 
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ABSTRACT: 
BACKGROUND 
Intravenous or intracoronary adenosine is used in the cardiac catherization lab to achieve 
maximal coronary blood flow and determine fractional flow reserve.     
OBJECTIVE    
To determine the stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride 
injection or 5% dextrose injection in polyolefin infusion bags stored at two temperatures, 
refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C). 
METHODS 
Adenosine 10 µg/mL and 50 µg/mL solutions were prepared in 50 mL polyolefin infusion 
bags containing 0.9% sodium chloride injection or 5% dextrose injection and stored at 
controlled room temperature (20 - 25 ºC) or under refrigeration (2 - 8 °C). Each combination 
of concentration, diluent, and storage was prepared in triplicate.  Samples were assayed using 
a stability-indicating, reversed-phase high performance liquid chromatography immediately 
at time zero and at 24 hours, 48 hours, 7 days, and 14 days.  Stability was defined as 
retaining 90% - 110% of the initial adenosine concentration. The samples were also visually 
inspected against a light back ground for clarity, color, and the presence of particulate matter.   
RESULTS 
After 14 days, all samples retained 99 - 101% of the initial adenosine concentration. No 
considerable change in pH or visual appearance was noted.  The stability data indicated no 
significant loss of drug due to chemical degradation or physical interactions during storage. 
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CONCLUSION 
Adenosine solutions of 10 and 50 µg/mL were stable for at least 14 days in 50 mL polyolefin 
infusion bags of 0.9% sodium chloride injection or 5% dextrose injection stored at controlled 
room temperature and refrigerated conditions. 
Key Words:  adenosine, stability, concentration, fractional flow reserve 
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INTRODUCTION: 
Adenosine, an endogenous nucleoside, is clinically used to convert paroxysmal 
supraventricular tachycardia (PSVT) to sinus rhythm by slowing the conduction time through 
the AV node and by interrupting the reentry pathway.1  In vivo, it is synthesized in the 
myocardium and is released in response to increased metabolic oxygen demands and 
ischemia.  Adenosine administration results in coronary vasodilation and increased blood 
flow.2  Its pharmacological properties allows for its use in the measurement of fractional flow 
reserve (FFR) in patients with multivessel coronary artery disease who are undergoing 
percutaneous coronary intervention (PCI).3,4  FFR indicates stenosis severity by determining 
the ratio of the maximal blood flow in a diseased vessel to the maximum blood flow in the 
same vessel without stenosis.  The calculation of FFR allows clinicians to accurately identify 
specific lesions most likely to induce myocardial ischemia.2 
Currently, administrations of intravenous and intracoronary adenosine are used in a 
cardiac catherization setting to achieve maximal coronary blood flow and determine FFR.  
Since adenosine requires continuous infusion administration and is used in an emergency 
setting, stability information would be beneficial for cost saving and accelerated medication 
delivery time.  Two previous stability studies of diluted solutions of adenosine have 
demonstrated stability with the following concentrations: 50, 100, 200, and 750 µg/mL.5,6  
Because no information is available on the stability of adenosine solutions at lower 
concentrations, the purpose of this study was to determine the stability of adenosine 10 
µg/mL and 50 µg/mL solutions in 50 mL polyolefin infusion bags containing 0.9% sodium 
chloride injection or 5% dextrose injection at controlled room temperature (20 - 25 ºC) or 
under refrigeration (2 - 8 °C).  
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METHODS: 
RP-HPLC: 
A Shimadzu model LC-2010A HT HPLC instrumenta with a C18, 4.6x150 mm, 3 µm, 
100 A columnb and a guard cartridge systemc with a C18, 4x3 mm cartridge maintained at 40 
°C was used for this study.  The instrument contained a degasser, autosampler, and UV 
detector, set at 259 nm. A stability-indicating reverse phase high performance liquid 
chromatography (RP-HPLC) method was created and used.  Data collection and processing 
was done using Shimadzu LC Solution software.  The mobile phase consisted of methanold 
and distilled water (7:93 v/v) with 0.1% trifluoroacetic acide.  Adenosine was eluted at a flow 
rate of 0.5 mL/min after an injection of 10 µL. Under these conditions, adenosine eluted with 
an average retention time of 7 minutes.   
Five standard solutions of adenosine, with concentrations of 1, 5, 10, 30, and 50 µg/mL, 
were prepared from 100 µg/mL stock solution with distilled water and used to establish 
linearity r2 > 0.999 of the detector response.  The 100 µg/mL adenosine stock solution was 
prepared using 10 mg of adenosine powderf in 100 mL volumetric, using distilled water to 
make up the volume.  These standards were passed through 0.45 µm, 13 mm diameter 
disposable nylon syringe filtersg and assayed by RP-HPLC in triplicate on three separate 
days.  Six sets of filtered standards were frozen in HPLC vials for use at each time point in 
the stability study after linearity was established following the first day’s successful runs.  
Intra-day and inter-day variability was determined and is depicted in Tables 1 and 2, 
respectively. 
TABLE 1. 
Intraday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL 
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TABLE 2.  
Interday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL 
 
A forced degradation study was performed to verify that the assay was stability-
indicating, with the ability to resolve degradation products from the parent compound.  A 100 
µg/mL adenosine stock solution was again used.  From this stock solution, four 10 µg/mL 
solutions of 10 mL each were prepared using distilled water as the diluents and treated under 
separate conditions.  Four samples were prepared as follows: sample one was adjusted to pH 
2 with 1 M hydrochloric acid and incubated at 60 ºC, sample two was adjusted to pH 12 with 
1 M sodium hydroxide and incubated at 60 ºC, sample three was spiked to a concentration of 
3% hydrogen peroxide and incubated at 60 ºC, and sample four was spiked to a concentration 
of 3% hydrogen peroxide and placed in direct sunlight.  RP-HPLC analysis was performed at 
time zero and at every 24 hours until at least 10% degradation had occurred, which occurred 
by the 72 hour time point.  All degradation products were well separated from the parent 
drug with retention times shorter than 6-min. 
 
STABILITY STUDY: 
The stability of adenosine 10 µg/mL and 50 µg/mL in 0.9% sodium chloride injection or 
5% dextrose injection in 50 mL polyolefin infusion bags stored at controlled room 
temperature (20 - 25 ºC) and refrigeration (2 - 8 ºC) was tested as follows. 
The average overfill volume of three 50 mL polyolefin infusion bags of 0.9% sodium 
chloride injection h and 5% dextrose injectioni was determined for the lots and expirations 
used for this stability study.  The average overfill of the 50 mL IV bag of 0.9% sodium 
chloride injection and 5% dextrose injection was 7.3 mL and 6.3 mL, respectively.  For the 
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two strengths being studied, the volume of overfill was withdrawn along with the volume of 
adenosine 3 mg/mL solutionj to be injected.  Adenosine 10 µg/mL and 50 µg/mL were 
prepared in triplicate in either 0.9% sodium chloride or 5% dextrose and stored at either 
controlled room temperature (20 - 25 ºC) or refrigeration (2 - 8 ºC), yielding a total of 24 
prepared samples.  In addition to this, each diluent was also stored under controlled room 
temperature (20 - 25 ºC) or refrigeration (2 - 8 ºC) without adenosine added, four more 
samples total, to serve as controls should unexpected results arise.  All preparations were 
made using aseptic techniques in a class II biological safety cabinetk.  At each stability time 
point, the samples were visually inspected for clarity, color, and presence of particulate 
matter; 2 mL was aseptically withdrawn for pH measurements and 1 mL for RP-HPLC 
analysis.   
The initial concentration of adenosine in solution was determined using the regression 
equation from the calibration curve, Concentration (µg/mL) = 65964/(Peak Area), from the 
time zero analyses as depicted in Figure 1.  Using the peak areas, % initial concentration 
remaining was determined using the average of the triplicate ± standard deviation.  Both 
initial concentration and percent initial concentration are depicted in Table 3.  For this study, 
stability was defined as 90% - 110% of the time zero concentration with no significant 
changes in visual appearance or pH. 
FIGURE 1. 
Calibration Curve 
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TABLE 3.  
Stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5% 
dextrose injection in polyolefin infusion bags stored at two temperatures, refrigeration (2 - 8 
°C) or at controlled room temperature (20 - 25 °C). 
 
pH MEASUREMENTS: 
For each sampling time, the pH meterl was calibrated with pH 4m and pH 7n buffer 
solutions, yielding a slope ≥97% at 25 ºC.  The average pH values for each triplicate ± 
standard deviation were determined and are depicted in Table 4.  For this study, stability was 
defined as a pH measurement consistent with the package labels of each component used, 
specifically 3.5 to 7.5.1,7,8 
 
TABLE 4. 
Stability Study pH Measurements of adenosine 10 and 50 µg/mL in either 0.9% sodium 
chloride injection or 5% dextrose injection in polyolefin infusion bags stored at two 
temperatures, refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C). 
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RESULTS AND DISCUSSION: 
All solutions were visually clear, colorless, and free of particulate matter at all time 
points.  The initial pH values of the samples were consistent with the acceptable pH ranges 
specified in the package insert, i.e. pH 4.5 – 7.0 for 9% sodium chloride injection and pH 3.5 
– 6.5 for 5% dextrose injection.  There was no considerable change in pH observed 
throughout the study as shown in Table 4.  All samples retained greater than 90% of the 
initial concentration at all time points, suggesting little to no loss of adenosine due to 
chemical degradation or physical adsorption to polyolefin infusion bags packaging as shown 
in Table 3. 
In future studies, it would be beneficial to perform this study with the use of PVC bags, 
which are less expensive and more commonly seen in the hospital setting in order to obtain a 
complete range of stability data.  Alhough polyvinyl chloride (PVC) IV bags were 
unavailable at the time of this study, the use of polyolefin infusion bags provides unique 
stability data.  In recent years, there has been a shift for many hospitals to use DEHP-free IV 
bags, as the plasticizer has been shown to have effects on the development of the male 
reproductive system and production of normal sperm in young laboratory animals.9  
Polyolefin infusion bags consist of a polymer of ethylene and propylene and are latex-free, 
PVC-free, and DEHP-free.  The plastic container is developed for parenteral medication and 
is commonly referred to as PAB® infusion bags.7, 8  The copolymer contains no plasticizers 
and exhibits no leachability, which can be considered an advantage when preparing a low-
concentration adenosine formulation.    
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CONCLUSION: 
Adenosine solutions of 10 and 50 µg/mL concentrations in 50 mL polyolefin infusion 
bags of 0.9% sodium chloride injection and 5% dextrose injection were stable when stored in 
the refrigerator or at controlled room temperature for a period of up to 14 days.  
 
FOOTNOTES: 
aHPLC 2010A with LCSolutions. Shimadzu Scientific Instruments, Marlborough, MA. 
bLuna C18 column (3 µm particle size, 4.6 mm x 150 mm). Phenomenex, Inc, USA. 
cSecurityGuard Cartridge C18 (3 mm x 4 mm). Phenomenex, Inc, USA. 
dMethanol HPLC Grade. Fisher Scientific, Fair Lawn, NJ, lot 115982. 
eTrifluoroacetic acid, 99%. ACROS Organics, NJ, lot B0517715. 
fAdenosine, 99+%. ACROS Organics, NJ, lot A0263503. 
g13 mm Syringe Filter (0.45 µm, Nylon, Non-Sterile). Fisherbrand, Ireland, lot R9PN60120. 
h0.9% sodium chloride injection in PAB® container (copolymer of ethylene and propylene). 
 B.Braun Medical Inc.., Irvine, CA, lot J2D929. 
i5% dextrose injection in PAB® container (copolymer of ethylene and propylene). B.Braun 
 Medical Inc., Irvine, CA, lot J2C904. 
jAdenosine injection 3 mg/ml, USP. APP Pharm, Schaumburg, IL, lot 6003500. 
kESCO Airstream Class II Biological Safety Cabinet. ESCO Technologies, Hatboro, PA. 
lSevenEasy pH meter. Mettler-Toledo Inc., Columbus, OH. 
mBuffer solution pH 4.00. Fisher Scientific, Fair Lawn, NJ, lot 085812. 
nBuffer solution pH 7.00. Fisher Scientific, Fair Lawn, NJ, lot 084727. 
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TABLE 1. 
Intraday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL 
 
Concentration 
(mcg/mL) 
Peak Area SD %CV Run #1 Run #2 Run #3 Average 
0 0 0 0 0 - - 
1 63068 63114 62911 63031 106 0.17 
5 313430 315180 316161 314924 1383 0.44 
10 632797 635095 634614 634169 1212 0.19 
30 1964048 1966455 1967198 1965900 1647 0.08 
50 3285579 3294835 3295877 3292097 5669 0.17 
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TABLE 2. 
Interday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL 
 
Concentration 
(mcg/mL) 
Peak Area 
Interday 
SD 
Interday 
%CV 2012/05/29 Average 
2012/05/31 
Average 
2012/06/02 
Average 
Interday 
Average 
0 0 0 0 0 - - 
1 63392 63031 62325 62916 542.75 0.86 
5 315309 314924 312673 314302 1423.45 0.45 
10 635441 634169 632286 633965 1587.31 0.25 
30 1966374 1965900 1966368 1966214 271.56 0.01 
50 3297544 3292097 3291768 3293803 3244.06 0.10 
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TABLE 3. 
Stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5% 
dextrose injection in polyolefin infusion bags stored at two temperatures, refrigeration (2 - 
8°C) or at controlled room temperature (20 - 25°C). 
 
Concentration 
(mcg/mL) 
Diluent 
(50 mL IV bag) 
Storage 
(°C) 
Actual Initial 
Adenosine 
Concentration 
(mcg/mL) 
% Initial Concentration Remaining 
24 hours 48 hours 7 days 14 days 
 
10 
 
 
NS 
25 10.33 ± 0.41 100.4 ± 0.1 101.0 ± 0.0 100.7 ± 0.3 100.1 ± 0.1 
5 10.05 ± 0.39 100.4 ± 0.1 100.8 ± 0.2 100.8 ± 0.2 100.1 ± 0.1 
D5W 
25 10.03 ± 0.32 100.4 ± 0.1 100.4 ± 0.1 100.0 ± 0.6 99.2 ± 0.1 
5 10.43 ± 0.20 100.0 ± 0.2 100.1 ± 0.1 99.8 ± 0.1 99.7 ± 0.1 
 
50 
 
 
NS 
25 48.97 ± 1.07 100.1 ± 0.0 100.1 ± 0.8 100.1 ± 0.8 100.1 ± 0.1 
5 48.45 ± 0.59 100.2 ± 0.1 100.2 ± 0.0 100.2 ± 0.0 100.0 ± 0.0 
D5W 
25 50.09 ± 1.37 100.1 ± 0.0 100.2 ± 0.1 99.7 ± 0.1 99.7 ± 0.2 
5 50.68 ± 1.96 100.0 ± 0.1 100.0 ± 0.1 99.8 ± 0.2 99.8 ± 0.1 
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TABLE 4. 
Stability Study pH Measurements of adenosine 10 and 50 µg/mL in either 0.9% sodium 
chloride injection or 5% dextrose injection in polyolefin infusion bags stored at two 
temperatures, refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C). 
 
 
Concentration 
(mcg/mL) 
Diluent 
(50 mL IV bag) 
Storage 
(°C) 
 pH (Mean ± SD) 
0 hours 24 hours 48 hours 7 days 14 days 
10 
NS 
25 4.94 ± 0.21 5.08 ± 0.08 4.95 ± 0.06 4.97 ± 0.02 5.02 ± 0.05 
5 4.77 ± 0.03 4.98 ± 0.01 4.90 ± 0.02 4.96 ± 0.02 4.95 ± 0.02 
D5W 
25  4.43 ± 0.03 4.45 ± 0.02 4.43 ± 0.01 4.43 ± 0.00 4.48 ± 0.03 
5 4.43 ± 0.01 4.45 ± 0.03 4.42 ± 0.01 4.44 ± 0.02 4.50 ± 0.02 
  
50  
NS 
25 4.93 ± 0.01 5.06 ± 0.04 5.00 ± 0.02 5.07 ± 0.02 5.08 ± 0.02 
5 4.88 ± 0.02 5.04 ± 0.03 4.97 ± 0.01 5.05 ± 0.03 5.09 ± 0.01 
D5W 
25 4.55 ± 0.01 4.56 ± 0.01 4.54 ± 0.00 4.55 ± 0.01 4.60 ± 0.01 
5 4.52 ± 0.03 4.57 ± 0.01 4.53 ± 0.01 4.55 ± 0.01 4.61 ± 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
